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ABSTRACT: Drug−target binding kinetics are an important predictor of in vivo drug efficacy, yet the relationship between
ligand structures and their binding kinetics is often poorly understood. We show that both rupatadine (1) and desloratadine (2)
have a long residence time at the histamine H1 receptor (H1R). Through development of a [
3H]levocetirizine radiolabel, we
find that the residence time of 1 exceeds that of 2 more than 10-fold. This was further explored with 22 synthesized rupatadine
and desloratadine analogues. Methylene-linked cycloaliphatic or β-branched substitutions of desloratadine increase the
residence time at the H1R, conveying a longer duration of receptor antagonism. However, cycloaliphatic substituents directly
attached to the piperidine amine (i.e., lacking the spacer) have decreased binding affinity and residence time compared to their
methylene-linked structural analogues. Guided by docking studies, steric constraints within the binding pocket are hypothesized
to explain the observed differences in affinity and binding kinetics between analogues.
■ INTRODUCTION
Drugs have to bind a therapeutically relevant target to exhibit a
biological effect and, as such, target binding is well
characterized during the development process of many drugs.
The binding affinity is an often-used parameter to measure
drug binding to a target (quantified as KD or Ki values),
implicitly assuming ligand binding occurs under equilibrium
conditions. However, drug pharmacodynamics can also be
characterized by the drug−target binding kinetics, which
provide important details about the mechanism of target
binding, unexplained by solely the binding affinity.1−3 The
drug−target residence time, which is a measure for the lifetime
of a drug−target complex, is currently discussed as one of the
important contributors to the biological efficacy of drugs in
vivo.3−10 It has been postulated that a suitably long drug−
target residence time might increase the therapeutic window in
vivo when clearance of the drug is faster than the dissociation
of the drug from the receptor.11,12 In such cases, drug action
would last longer than the presence of free drug plasma
concentrations (i.e., hysteresis). Thus, duration of therapeutic
action may not only depend on drug absorption, distribution,
metabolism, and excretion (and the nature of its metabolites),
but can also be a direct effect of prolonged target binding.13−15
As the target of 33% of all small-molecule drugs, G protein-
coupled receptors (GPCRs) are an important class of proteins
in drug discovery.16 The histamine H1 receptor (H1R) is an
archetypical GPCR and is successfully targeted by antagonists
for the treatment of, for example, allergic disorders.17 A long
duration of action has been observed in vivo for second-
generation H1R antagonists like levocetirizine and fexofena-
dine, which have a long residence time at the H1R.
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Hysteresis was indeed observed for levocetirizine and
fexofenadine.18−20 A strong hysteresis of H1R antagonism
has also been shown for rupatadine (1), which antagonizes the
histamine-induced flare response up to 72 h after oral
administration, whereas plasma levels could only be detected
up to 12 h after administration.21 This might be explained by
the metabolism of rupatadine to metabolites such as
desloratadine (2), which is a known antihistamine itself with
a long H1R residence time (>1 h) and a long plasma half-life in
vivo (human).19,21−27 Yet, a potentially long drug−target
residence time of rupatadine may also be a crucial contributing
factor to its observed long duration of action.
Here, we report the measurement of the residence times of
rupatadine and desloratadine at the H1R. It was shown that
rupatadine has a ≥10-fold longer residence time at the H1R,
relative to desloratadine. As a consequence, rupatadine
completely antagonized the histamine-induced calcium mobi-
lization in HeLa cells for >2 h after removal of unbound
antagonist, whereas inspected under the same conditions,
desloratadine allowed a time-dependent gradual recovery of
the histamine-induced response. To understand the structure−
kinetics relationship (SKR) for rupatadine and desloratadine in
more detail, the binding kinetics at the H1R were characterized
for newly synthesized analogues (3−24) that retain the core
scaffold of 1 and 2 but contain a diverse set of aromatic and
aliphatic N-substituents on the piperidine ring. It was shown
that relatively small aliphatic N-substitutions were sufficient for
a prolonged H1R residence time compared to desloratadine,
unless this was negated by steric interference in the binding
pocket.
■ RESULTS
Binding Properties of Rupatadine and Desloratadine
at the H1R. Based on the long duration of action of rupatadine
in vivo,21 we hypothesized that it would exhibit a long
residence time at the H1R. Therefore, binding of rupatadine
and its structural analogue desloratadine to the human H1R
was investigated, initially using [3H]mepyramine and stand-
ardized competition binding experiments.26 The H1R binding
affinity of desloratadine (pKi 9.1 ± 0.1) determined in these
experiments was consistent with previously reported affinity
values (pKi = 8.8−1024−26). Rupatadine (pKi 8.4 ± 0.1) was
shown to have a 5-fold lower binding affinity for the H1R than
desloratadine. To the best of our knowledge, the binding
affinity of rupatadine on the human H1R has not been reported
in the literature. Its H1R activity on guinea pig ileum is known,
as well as that for a series of derivatives.28
Competitive association experiments were subsequently
performed to examine the binding kinetics of rupatadine and
desloratadine at the H1R. Initially, [
3H]mepyramine was
selected as radioligand and experiments were performed at
25 °C with an 80 min incubation time, in the manner
described previously.26 A clear initial overshoot in [3H]-
mepyramine binding was observed for both unlabeled ligands
(Figure 2A), which is indicative of the long residence times of
the unlabeled ligands relative to [3H]mepyramine.29,30
However, since the binding curves of rupatadine and
desloratadine showed similar overshoot patterns, it was difficult
to discern differences in their binding kinetics using the
Motulsky−Mahan analysis.30 Desloratadine was found to have
a residence time of 190 ± 40 min (similar to that reported in
the literature25,26), but for rupatadine, the koff value (and thus
the residence time) could not be accurately constrained by the
model. To overcome this limitation, it was speculated that the
residence times of desloratadine and rupatadine at the H1R
might be better discriminated using a radioligand with a longer
residence time, and one more closely matched to desloratadine
and rupatadine than mepyramine.31 With this in mind,
levocetirizine was considered a better alternative as it is
known to have a 100-fold longer residence time at the H1R
than mepyramine.25 Radiolabeled levocetirizine has previously
been disclosed but without synthetic details for its prepara-
tion.25 The radiolabel was prepared by us using a six-step
sequence progressing through intermediates 25−28. Separa-
tion of the enantiomers of 28, followed by Pd-catalyzed
dehalotritiation of the corresponding aryl iodide delivered the
ligand with a specific activity of 956 GBq mmol−1 (Scheme 1
and Supporting Information).
[3H]Levocetirizine was then employed in competitive
association experiments to characterize the binding kinetics
of rupatadine and desloratadine using an incubation time of 6
h (to ensure a steady state in [3H]levocetirizine binding). In
the presence of desloratadine, [3H]levocetirizine binding to the
H1R increased gradually over time, whereas in the presence of
Scheme 1. Synthesis of [3H]Levocetirizinea
aKey: (a) Et2O, 0 °C to room temperature (rt), 16 h, 88 %; (b) SOCl2, dichloromethane (DCM), rt, 20 h, 95 %; (c) 2-(piperazin-1-yl)ethanol,
PhMe, 80 °C, 20 h, 21 %; (d) (1) KOH, dimethylformamide (DMF), 0 °C, 90 min; (2) sodium 2-chloroacetate, DMF, 0 °C, 3 h, 57 %; (e) chiral
separation; (f) T2, Pd/C (10 %), Et3N, EtOH.
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rupatadine, a clear initial overshoot in [3H]levocetirizine
binding was observed (Figure 2). Based on these curve shapes,
it is clear that rupatadine has a longer residence time on the
H1R than desloratadine. Fitting the data to the Motulsky−
Mahan model30 did not result in a precise fit of the koff values,
but indicated the koff of desloratadine at the H1R to be >0.03
min−1 (P = 95% in all three experiments) corresponding to a
residence time of <33 min. In the case of rupatadine, the koff
value at the H1R is <0.0033 min
−1 (P = 95% in all three
experiments), which corresponds to a residence time of >300
min. Thus, rupatadine has a very long residence time at the
H1R, which is at least 10-fold longer than that observed for
desloratadine.
Design and Synthesis of Rupatadine Analogues at
the H1R. To identify the structural features that drive the
longer residence time of rupatadine compared to desloratadine
at the H1R, various analogues were synthesized and
pharmacologically characterized.
Rupatadine contains a 5-methylpyridin-3-yl group connected
through a methylene to the basic amine of desloratadine
(Figure 1). To study the SKR, we synthesized analogues with
the methyl group on different positions of the pyridine ring
(3−5), and the pyridine analogue without the methyl group
(6). Two positional isomers of 6 (7, 8) and two pyrimidines
(9−10) were also prepared. Additionally, the pyridine ring of
rupatadine was replaced by a phenyl ring with (11), or without
(12), a 3-methyl group. Finally, to gradually bridge the
transition to 2, a set of analogues was synthesized, in which the
basic amine of desloratadine was substituted with a range of
alkyl groups (13−24), varying in size, level of constrainment,
and point of attachment (with or without the one-carbon
spacer). Of these, only 3−8, 12, 23, and 24 have been reported
before.28,32−35
All rupatidine analogues were efficiently obtained in one step
from commercially available desloratidine (2), as depicted in
Scheme 2. Compounds 4−8, 11−12, and 16 were obtained via
nucleophilic substitution of the corresponding alkyl bromides
in moderate to good yields (36−86%). Reductive alkylation of
2 with different aromatic aldehydes afforded 3, 9, and 10 (64−
88% yield). Compounds 13−15, 17−20, 22, and 23 were
synthesized by reductive alkylation using aliphatic carbonyl
compounds in acceptable to good yields (52−71%). Methyl
derivative 24 was obtained as the fumarate salt from aqueous
(aq) formaldehyde and NaBH(OAc)3 in 60% yield. Attempted
synthesis of cyclopropyl-substituted analogue 21 via alkylation
of 2 with cyclopropylbromide failed. However, reductive
alkylation of 2 with (1-ethoxycyclopropoxy)triethylsilane
delivered the desired product, albeit in low isolated yield
(17%).36
Pharmacological Characterization. H1R Binding Affin-
ity. All rupatadine analogues containing an aromatic group (3−
12) had comparable binding affinities at the H1R (pKi 7.9−
8.5) as rupatadine, which were 4−16-fold lower than the
binding affinity of desloratadine (pKi = 9.1). Substituting the
benzene of 12 for a cyclohexane (13) did not affect the
binding affinity (<2-fold). However, substituting the benzene
of 12 for smaller methylene-linked cycloaliphatic N sub-
stituents (14, 16, and 17) resulted in 2−6-fold higher binding
affinities at the H1R, similar to the binding affinity of
desloratadine. Likewise, analogues 22−24 with small acyclic
aliphatic substituents had a high binding affinity at the H1R as
well (pKi 9.0−9.4), again similar to that of desloratadine (pKi
9.1). Interestingly, the one-carbon linker between the basic
amine and the cyclic aliphatic substituents of 13, 14, 16, and
17 is important for a high-affinity binding, since a 2−8-fold
reduced binding affinity is observed for analogues that lack this
spacer (18−21, respectively).
Analysis of Binding Kinetics. To explore the relative
residence time of all analogues, a dual-point competition
association was performed to determine the kinetic rate index
(KRI).29 This methodology is based on the initial overshoot in
radioligand binding when co-incubated with an unlabeled
ligand, which is an indicator of a relatively long residence time
of the unlabeled ligand compared to that of the radioligand
(Figure 2). The overshoot is quantified by measuring the
radioligand binding at two time points. The ratio in
[3H]levocetirizine binding at both time points (1 and 6 h) is
>1 for unlabeled ligands that cause an initial overshoot in
[3H]levocetirizine binding and hence have a relatively long
residence time compared to [3H]levocetirizine. Using this
assay setup, a KRI value of 0.9 ± 0.1 was obtained for
unlabeled levocetirizine, demonstrating that, as expected, it has
a residence time essentially the same as the radioligand.
Desloratadine does not cause an initial overshoot in [3H]-
levocetirizine binding (Figure 2B) and has a KRI value of 0.82
± 0.04. In contrast, rupatadine binds the H1R with a much
longer residence time (Figure 2B), which is indeed reflected by
its KRI value of 2.3 ± 0.2 (Table 1). The KRI values for all
analogues are given in Table 1. All analogues with an aromatic
substituent (3−12) show KRI values >1, indicative of a
consistently long residence time at the H1R (Table 1). More
notably, among the analogues with aliphatic substitutions on
the piperidine ring (1, 2, 13−24), large differences in the KRI
values were observed (Figure 3). This intriguing SKR in the
aliphatic series, in combination with the lack thereof in the
aromatic series, led us to focus on the former series.
Figure 1. Structures of the investigated H1R antagonists and
synthesized structural analogues.
Scheme 2. Synthesis of Rupatadine Analoguesa
aKey: (a) K2CO3, DMF, rt, 18 h, 36−86%; (b) NaHB(OAc)3,
dichloroethane (DCE), rt, 14 h, 64−88%; (c) NaHB(OAc)3, DCE, rt,
14 h, 52−71%; (d) NaHB(OAc)3, MeOH, DCM, AcOH, rt, 1.5 h,
60% as fumarate salt; (e) NaHB(OAc)3, AcOH, DCM, rt, 48 h, 17%.
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Analogues with cycloaliphatic groups and a one-carbon
spacer (13, 14, 16, and 17) show high KRI values, also
indicating a long residence time on the H1R. However,
structural analogues with the same cycloaliphatic group
without the one-carbon spacer (18−21) show similar KRI
values to desloratadine, indicative of a shorter residence time at
the H1R. Additionally, analogues with small acyclic aliphatic
substituents (22−24) had an average KRI value slightly larger
than 1, implying an increased residence time at the H1R
compared to desloratadine. The correlation between affinity
and residence time parameters of GPCR ligands and the
physicochemical properties of the ligands has been inves-
tigated, including affinities for H1R receptor antagonists,
37,38
by various research groups.39−46 Therefore, we investigated
whether correlations exist between our pKi/KRI values and key
physicochemical parameters (logD7.4, polar surface area, van
der Waals volume, pKa value of the conjugate acid of the
piperidine nitrogen atom). However, Figure S1, Tables S1 and
S2, show that no strong correlations are evident.
Duration of Functional H1R Antagonism. Since large
differences were observed in the KRI values of the aliphatic
rupatadine analogues, these differences were explored in more
detail by measuring the kinetics of functional H1R antagonism
following a preincubation with the selected analogues of
interest. The functional recovery time (RecT) of the H1R was
previously shown to be correlated with the residence time of
antagonists.47 As such, HeLa cells, with endogenous expression
of the H1R, were preincubated with 10 times the Ki
concentration of the respective compound. Unbound ligands
were then depleted by washing the cells, which were
subsequently stimulated after different incubation times with
10 μM histamine. The intracellular calcium mobilization
following administration of histamine was determined with
the calcium-sensitive fluorescent dye (Fluo4 NW).
Preincubating HeLa cells with desloratadine, which has a
low KRI value (<1), resulted in functional recovery of the H1R
over time (Figure 4A and Table S1). However, cells pretreated
with rupatadine were completely unresponsive to histamine,
for at least 2 h after removing unbound rupatadine, suggesting
very persistent target engagement by rupatadine. In Figure 4B,
the functional recovery of the H1R is compared after
pretreating the cells with analogues containing cycloaliphatic
N substituents on the piperidine with or without a one-carbon
spacer. Analogues with a one-carbon spacer (14, 16, and 17)
completely abolished the histamine-induced calcium response
for at least 2 h, similarly to rupatadine. In contrast, and in line
with the measured KRI values, removing the one-carbon spacer
(19−21), allowed a relatively fast functional recovery of the
histamine response.
The differences in the combined kinetic/affinity binding
profiles of the compounds were further explored on a structural
level with docking studies. Using the X-ray crystal structure of
the H1R with the structurally related ligand doxepin bound,
48
reference compounds desloratadine, rupatadine, as well as all
analogues (3−24) were docked using PLANTS.49 Figure 5
shows the postulated binding modes of desloratadine,
rupatadine, and the representative pair 14/19, in comparison
to the binding mode of the co-crystallized ligand doxepin.
Desloratadine likely adopts a similar binding pose to doxepin
in the H1R crystal structure (Figure 5A). Rupatadine was also
found to adopt a similar binding mode to doxepin, but its (5-
methylpyridin-3-yl)methyl moiety targets an additional area of
the H1R binding pocket toward the extracellular vestibule
(Figure 5B). Since the available space in the H1R pocket next
to the amine-binding region is limited by I4547.39 and Y4587.43,
it is postulated that the cyclopentyl substituent of 19
encounters greater steric hindrance than the cyclopentylmethyl
substituent of 14 (Figure 5C), in line with the altered H1R
binding characteristics of 19 (Figures 3 and 4B). This steric
hindrance results in a tilted binding mode compared to
desloratadine, which is not observed for optimal binding of
analogues with a methylene spacer between the desloratadine
scaffold and the cyclopentyl group (14, Figure 5D). The spacer
allows the aliphatic group to turn toward the extracellular
vestibule (in the direction of H4507.35), where more room is
available, possibly preventing a steric clash with I4547.39 and
Y4587.43 (Figure 5D).
■ DISCUSSION AND CONCLUSIONS
A long drug−target residence time has been postulated to
benefit the in vivo efficacy of several drugs for a broad number
of drug targets, among which is the H1R.
3,4,7,50,51 Affinity-based
optimization of drug binding does not necessarily reflect
differences in target residence time,52,53 and a discrepancy
between affinity and residence time at the H1R was previously
described. Moreover, in the case of ligands that do not reach a
binding equilibrium within the time frame of a binding
experiment, i.e., ligands with a very slow off rate like
rupatadine, pKi will be underestimated.
54 The drug−target
residence time can therefore provide additional information for
Figure 2. Radioligand association binding when co-incubated with rupatadine and desloratadine. A homogenate of HEK293T cells expressing the
H1R was incubated with: (A) [
3H]mepyramine (3.8 nM) alone, or in the presence of either rupatadine (130 nM) or desloratadine (4 nM) or (B)
[3H]levocetirizine (6.6 nM) alone, or in the presence of either rupatadine (6 nM) or desloratadine (0.7 nM). Representative graphs of three
experiments are shown depicting individual measurements with duplicate values per time point.
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the optimization of drugs that would be lost by focusing on
only the binding affinity. Since the residence time is not
routinely incorporated in drug development, design strategies
for optimizing the drug−target residence time of lead
compounds are not widely available. Since rupatadine is
shown here to have a much longer residence time at the H1R
than its close structural analogue desloratadine, despite a
reduced binding affinity, it provides an opportunity for a
detailed investigation of the SKR for this GPCR. Toward this
end, we synthesized [3H]levocetirizine, which proved to be a
useful tool to map the differences in the KRIs between the two
antihistamines. It was therefore employed to determine the
Table 1. H1R Binding of Rupatadine and Desloratadine Analogues
c
aFumarate salt. bPreviously reported (see text for references). cBinding affinity (pKi) values were determined by competition binding experiments
using [3H]mepyramine, and KRI values were determined by dual-point competition association experiments using [3H]levocetirizine. Depicted
values represent the mean ± standard error of the mean (SEM) of ≥3 experiments
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relative residence times of structural analogues 3−24. Several
analogues of rupatadine were designed to replace the (5-
methylpyridin-3-yl)methyl group with other aromatic moieties
(3−12). Interestingly, the Ki values of 3−12 are within 4-fold
of the Ki value of rupatadine. Additionally, all aromatic
analogues have a long apparent residence time, as is reflected
by the KRI > 1. Removing the aromatic character of the
functional group of 12 by replacing it with a cyclohexyl group
(13) does not affect the observed H1R binding properties
either. Hence, the strong effect on the residence time by the
(5-methylpyridin-3-yl)methyl group of rupatadine (compared
to desloratadine) cannot be explained by the aromatic
character, nor by the pyridine nitrogen atom and the methyl
substituent.
To further probe the SKR between rupatadine and
desloratadine, a series of analogues were characterized that
had different aliphatic substituents on the piperidine group
(13−24). Strikingly, most aliphatic moieties afford an increase
in the KRI compared to desloratadine, whereas the binding
affinity remains similar or even decreases. For example, 13−15
contain relatively large aliphatic substituents (≥6 carbons) and
have a slightly reduced binding affinity (pKi 8.6−8.9) and a
high KRI (>1.4) compared to desloratadine. Moreover,
analogues with small (≤3 carbons) acyclic aliphatic sub-
stituents (22−24) have a similar binding affinity but still a
slightly higher KRI compared to desloratadine. This suggests
that growing an aliphatic group from the piperidine increases
the residence time at the H1R. This trend is disrupted,
however, for analogues that contain cycloaliphatic groups
directly substituted on the amine (18−21) instead of being
separated from the amine by a one-carbon spacer (13, 14, 16,
and 17). Analogues without the methylene spacer (18−21) are
marked by a diminished KRI and binding affinity compared to
analogues with a methylene spacer, whereas the KRI values are
of the same magnitude as desloratadine.
This cliff in the SKR trend was validated for a subset of
analogues by studying the kinetics of functional H1R
antagonism, which is known to reflect differential residence
times at the H1R.
47 Representative analogues in which the
cycloaliphatic group is substituted with a one-carbon spacer
(14, 16, and 17) completely inhibits the functional response of
the H1R for at least 2 h after removal of unbound ligands, as
was observed for rupatadine. In contrast, analogues with the
same cycloaliphatic groups without a one-carbon spacer (19−
21) allowed a clear recovery of the H1R functional response, as
was also observed for desloratadine. Hence, the relevance of
the methylene spacer for the binding kinetics of analogues with
relatively large N substituents was confirmed by the duration of
functional H1R inhibition.
The observed residence time/affinity cliff correlated with the
binding poses of the representative pair 14 and 19 in the H1R
binding pocket. Our docking studies suggest that the reduced
flexibility of the cycloaliphatic group without a spacer (19)
might lead to a suboptimal fit due to steric hindrance (Figure
5C,D). The increase in ligand residence time at the H1R, as
was observed for most analogues with an aliphatic group on
the basic amine of desloratadine (vide supra), seems therefore
to be mitigated when the shape of the H1R binding pocket, i.e.,
the steric constraints imposed by residues I4547.39 and
Y4587.43, is interfering with the binding position of the
desloratadine scaffold.
Recently, it has been shown that N-methylation of H1R
ligands with a primary or secondary amine increased the
binding affinity at the H1R by displacing a water molecule near
I4547.39.43 However, this effect on the binding affinity was not
observed for analogues with a chlorine moiety on the aromatic
rings. Consistent with this finding, N-methylation of
desloratadine (which contains a chlorine group), affording
24, had only modest effects on the H1R binding affinity.
Interestingly, 24 did have a higher KRI compared to
desloratadine but not to the same extent as was observed for
larger aliphatic substituents (for example, 13−17). Substitu-
tion with aliphatic or aromatic groups on the piperidine
possibly reduces the resolvation of both the ligand and binding
site during a dissociation event. For ligand dissociation from
the CRF1R, for example, a low degree of ligand solvation
during egress from the pocket was related to a long residence
Figure 3. Aliphatic substituents on the basic amine of desloratadine
cause differential binding kinetics at the H1R. A homogenate of
HEK293T cells expressing the H1R was incubated with [
3H]-
levocetirizine and the respective ligands. Binding of [3H]levocetirizine
was determined after 1 and 6 h, and the KRI value was determined as
the ratio in [3H]levocetirizine binding at both time points (6/1 h).
The bars depict the mean and SEM of ≥3 experiments. The top and
bottom dotted lines represent the KRI of reference ligands 1 and 2,
respectively.
Figure 4. Functional recovery of histamine-induced calcium
mobilization after a preincubation with ligands that bind the H1R.
HeLa cells were preincubated for 18−20 h with the respective H1R
ligand, reaching stable and high (±90%) occupancy of the
endogenously expressed H1R. The cells were then labeled with
Fluo4 NW in the presence of the respective ligands for 1 h. All excess
Fluo4 NW and unbound ligands were removed by wash steps and the
cells were subsequently stimulated with histamine (10−5 M) after
different incubation times. Representative graphs of ≥3 experiments
are shown, which depict the normalized calcium mobilization that was
measured at each time point after washout. (A) Cells were
preincubated with the reference H1R antagonists: rupatadine (1)
and desloratadine (2). (B) Cells were preincubated with compounds
having various cycloalkyl substituents on the basic amine with (14, 16,
17) or without (19, 20, 21) a one-carbon spacer.
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time at the receptor.41 Moreover, hydrophobic shielding of H
bonds can increase the lifetime of such interactions and
consequently result in an increased residence time.40 This is
corroborated by the fact that ligands with a relatively high KRI
(>1.5) were relatively lipophilic (log D7.4, Figure S1).
Considering that N substitution of H1R ligands was shown
to interfere with the water network in the binding site43 and
that the salt bridge between the basic amine of ligands and
D1073.32 is crucial for a high binding affinity at the receptor,42
shielding this interaction pair might prevent a rapid egress of
the ligands from the binding site.
In conclusion, compared to desloratadine, rupatadine has an
extremely long residence time at the H1R despite an apparent
loss in binding affinity, resulting in a longer duration of
functional H1R antagonism. Development of a [
3H]-
levocetirizine radiolabel allowed a detailed SKR study, which
shows that aliphatic N substitution of the piperidine ring from
desloratadine is enough to obtain antagonists with a long
residence time at the H1R without increasing the observed
binding affinity. Analogues with large flexible cycloaliphatic or
aromatic substituents, like the (5-methylpyridin-3-yl)methyl
substituent of rupatadine, have a long residence time at the
H1R. Notably, analogues with cycloaliphatic substituents
required an additional methylene spacer on the amine for an
optimal binding of the H1R. Modeling studies suggest that the
combined affinity/kinetics profiles of analogues without a
methylene spacer are possibly linked to the steric comple-
mentarity in the ligand−H1R complex. Aliphatic N substitution
of H1R antagonists is a new potential strategy to optimize the
residence time at the receptor. The presented SKR highlights
that subtle structural changes of small-molecule ligands can
have a profound effect on the binding kinetics at GPCRs.
■ EXPERIMENTAL SECTION
Pharmacological Assays. All compounds that were tested in
pharmacological assays (1−24, 28) are confirmed to pass a publicly
available pan-assay interference compounds filter.55,56
Radioligand Binding Experiments. Radioligand binding experi-
ments were performed as described before, with minor alterations.26
Cell pellets were produced from HEK293T cells expressing the N-
terminally HA-tagged H1R, and the pellets were stored at −20 °C.
Upon experimentation, the cells were thawed, resuspended in
radioligand binding buffer [Na2HPO4 (50 mM) and KH2PO4 (50
mM), pH 7.4], and homogenized with a Branson Sonifier 250
(Branson Ultrasonics, Danbury, CT). Cell homogenates (0.5−3 μg
per well) were then incubated with the respective ligands under gentle
agitation, as specified for the various assay formats below. After the
incubation time, binding reactions were terminated with the cell
harvester (PerkinElmer) using rapid filtration and wash steps over
polyethyleneimine-coated GF/C filter plates. Filter bound radioligand
was then quantified by scintillation counting using MicroScint-O and
the Wallac MicroBeta counter (PerkinElmer).
In competition binding experiments, cell homogenates were
incubated for 4 h at 25 °C with a single concentration of
[3H]mepyramine (1.5−4 nM) and increasing concentrations
unlabeled ligands (10−5−10−13 M). IC50 values were obtained by
analyzing the displacement curves with GraphPad Prism 7.03
(GraphPad Software, San Diego) and were converted to Ki values
using the Cheng−Prusoff equation.57
The binding rate constants of [3H]levocetirizine were determined
using the previously described methodology, by using four different
concentrations of [3H]levocetirizine (1−35 nM) for a total incubation
time of 360 min, with an incubation temperature of 37 °C (data not
shown).26 This resulted in a kon of 3.7 ± 0.4 106 min−1 M−1 and a koff
of 0.022 ± 0.003 min−1. In competitive association experiments with
[3H]levocetirizine as radioligand, cell homogenates were incubated at
37 °C for various incubation times with a single concentration of
[3H]levocetirizine (5−8 nM) in the absence of unlabeled ligand as
Figure 5. Proposed binding modes of (A) desloratadine (yellow), (B) rupatadine (salmon), and (C, D) compound 19 (orange) in comparison to
compound 14 (blue) based on docking49 into the crystal structure (PDB code 3RZE48) of the H1R in complex with doxepin [magenta; see (A)].
The clipped molecular surface of H1R highlights the limited space for growing from the amine of desloratadine due to I454
7.39 and Y4587.43. To
highlight the fit of the substituents of rupatadine (2, B), 19 (C), and 14 (D) compared to desloratadine in the H1R binding pocket, they are shown
as transparent surfaces.
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well as with three different concentrations of either desloratadine (2−
60 nM) or rupatadine (0.1−7 nM). The kon and koff values for the
binding of [3H]levocetirizine are constrained during the analysis of
the H1R binding kinetics of desloratadine and rupatadine. Kinetic
binding rate constants as well as their asymmetrical 95% confidence
intervals (95% CI) were determined using GraphPad Prism 7.03.
Since the 95% CI values were very broad, the values are depicted to
be higher or lower than the 95% CI boundary value observed over all
individually performed experiments. Graphs depict a representative
graph with mean and standard deviation of duplicate values showing,
for clarity, only a single concentration unlabeled ligand.
Competitive association experiments with [3H]mepyramine as
radioligand were performed as described before, with minor
alterations.26 Briefly, cell homogenates were incubated at 25 °C for
various incubation times with a single concentration of [3H]-
mepyramine (2.5−5.5 nM) in the absence or presence of a single
concentration unlabeled ligand [desloratadine (4−8 nM) or
rupatadine (80−250 nM)].
In dual-point competition association experiments, the kinetic rate
index (KRI) value at the H1R is determined. Cell homogenates were
incubated on a 96-well plate for 1 and 6 h at 37 °C, with a single
concentration of [3H]levocetirizine (4−11 nM) together with a single
concentration of unlabeled ligand that equals the respective Ki value
of that ligand at the H1R. All conditions were measured in triplicate
per experiment (n = 3). Additionally, for each 96-well plate,
[3H]levocetirizine was incubated with a large excess of mianserin
(10−5 M) to determine nonspecific binding levels of the radioligand
(n = 6) and, as a positive control, [3H]levocetirizine binding was
determined in the absence of competitor (maximal binding, n = 6).
[3H]levocetirizine binding levels were baseline-corrected by subtract-
ing nonspecific binding levels, and KRI values were then calculated by
the ratio of [3H]levocetirizine binding after a 1 h incubation time over
the [3H]levocetirizine binding after a 6 h incubation time. KRI is a
quantitative measure for the overshoot in radioligand binding, which
results from incubating the radioligand with an unlabeled ligand that
has a relatively low koff.
29,30 It is therefore crucial that the
concentrations of unlabeled ligands are comparable and lead to a
submaximal inhibition of the radioligand binding. Therefore KRI
values were only accepted when the % inhibition of [3H]levocetirizine
binding (compared to the maximal [3H]levocetirizine binding) was
(1) less than 80% after either 1 or 6 h and (2) more than 20%
inhibition after 6 h. In the case that data points had to be excluded,
the concentration unlabeled ligands were attenuated (ranging from 1
× Ki to 3 × Ki concentrations). All experiments were performed in
triplicate or more.
Intracellular Calcium Mobilization Assay. The functional
recovery of the H1R following antagonism was measured as described
before.47 In short, HeLa cells, endogenously expressing the H1R, were
seeded 2 × 104 cells per well in a clear bottom 96-well plate, which
were preincubated overnight with a concentration antagonist
corresponding to 10 times the respective Ki at the H1R (24 wells
per antagonist). After 18−20 h, the cells were labeled with the Fluo-
4NW dye in the presence of the respective concentration antagonist
for an hour. Both the excess dye solution and the unbound
antagonists were removed by washing the cells two times, and the
cells were then reconstituted in Hank’s balanced salt solution buffer
supplemented with probenecid (2.5 mM) (t0). Following the wash
step, the cells were stimulated every 5 min by histamine injection, into
a single well, using the NOVOstar plate reader (BMG Labtech,
Ortenberg, Germany), while simultaneously detecting the calcium-
mediated Fluo4 NW fluorescence (λexcitation = 494 nm and λemission =
516 nm). For each well stimulated with histamine, a consecutive
Triton X-100 injection after 65 s was used to lyse the cells leading to
saturation of the Fluo4 NW with calcium. The histamine-induced
peak response was then normalized to basal levels of fluorescence
(prior to histamine injection; 0) and saturated Fluo4 NW
fluorescence (following Triton X-100 injection; 1). This led to a
reproducible histamine-induced response over time for HeLa cells
pretreated with vehicle condition, which was set to 100%. Histamine-
induced peak responses were plotted against the difference in time
between t0 and the subsequent histamine injection. The recovery time
(RecT) was determined for antagonists by nonlinear regression using
the one-phase association model in GraphPad Prism 7.03.
Molecular Modeling. Simplified molecular-input line-entry
system for compounds 1−24 were obtained from ChemBioDraw
Ultra (version 16.0.1.4) and were subsequently used as input for
ChemAxon’s calculator for protonation (pH = 7.4). A three-
dimensional conformation was then generated using Molecular
Networks’ CORINA (version 3.49) and stored in Tripos MOL2
format (gold extension). The doxepin-bound H1R structure was
obtained from the protein data bank (PDB code 3RZE), after which
the fused T4-lysozyme was removed from the structure. The complex
was further prepared for docking using Molecular Operating
Environment (Chemical Computing Group, version 2016.0802).
Using PLANTS (version 1.2),49 each compound was docked into the
H1R binding pocket three times with the following settings: search
speed, 1; cluster root-mean-square deviation, 1.0; cluster structures,
10; and scored using the ChemPLP scoring function. The binding site
was defined by the center of the co-crystallized ligand doxepin with a
radius of 11 Å. The resulting docking poses were visually inspected,
and the poses with the best overlap with each other as well as the
doxepin reference compound were selected, which were also the
highest-ranking poses for each compound. Moreover, using an
interaction fingerprint similarity analysis,58 all docking poses were
compared to the binding mode of the co-crystallized compound
doxepin. All selected docking poses have an interaction fingerprint
similarity of at least 0.72 compared to the binding mode of doxepin
and are depicted in the Supporting Information (Figures S2 and S3).
The binding mode figures were created with PyMol (version 1.8.0).
Chemistry. General Procedures. Synthesis of Rupatadine
Analogues 3−24. Anhydrous tetrahydrofuran, DCM, DMF, and
Et2O were obtained by elution through an activated alumina column
prior to use. All other solvents and chemicals were acquired from
commercial suppliers and were used as received. ChemBioDraw Ultra
16.0.1.4 was used to generate systematic names for all molecules. All
reactions were performed under an inert atmosphere (N2). Thin-layer
chromatography analyses were carried out with alumina silica plates
(Merck F254) using staining and/or UV visualization. Column
purifications were performed manually using SiliCycle UltraPure
silica gel or automatically using Biotage equipment. NMR spectra (1H,
13C, and two-dimensional) were recorded on a Bruker 300 (300
MHz), Bruker 500 (500 MHz), or Bruker 600 (600 MHz)
spectrometer. Chemical shifts are reported in parts per million
(ppm) (δ), and the residual solvent was used as internal standard (δ
1H NMR: CDCl3 7.26; dimethyl sulfoxide (DMSO)-d6 2.50; CD3OD
3.31; δ 13C NMR: CDCl3 77.16; DMSO-d6 39.52; CD3OD 49.00).
Data are reported as follows: chemical shift (integration, multiplicity
(s = singlet, d = doublet, t = triplet, q = quartet, br = broad signal, m =
multiplet, app = apparent), and coupling constants (Hz)). A Bruker
microTOF mass spectrometer using electrospray ionization (ESI) in
positive-ion mode was used to record high-resolution mass
spectrometry (HRMS) images. A Shimadzu LC-20AD liquid
chromatograph pump system linked to a Shimadzu SPD-M20A
diode array detector with MS detection using a Shimadzu LC-MS-
2010EV mass spectrometer was used to perform liquid chromatog-
raphy−mass spectrometry (LC−MS) analyses. An Xbridge (C18) 5
μm column (50 mm, 4.6 mm) was used. The solvents that were used
were the following: solvent B (acetonitrile with 0.1% formic acid) and
solvent A (water with 0.1% formic acid), flow rate of 1.0 mL min−1,
start 5% B, linear gradient to 90% B in 4.5 min, then 1.5 min at 90% B,
then linear gradient to 5% B in 0.5 min, then 1.5 min at 5% B; and
total run time of 8 min. All compounds have a purity of ≥95% (unless
specified otherwise), calculated as the percentage peak area of the
analyzed compound by UV detection at 254 nm (values are rounded).
Reverse-phase column chromatography purifications were performed
using Buchi PrepChrom C-700 equipment with a discharge deuterium
lamp ranging from 200 to 600 nm to detect compounds using solvent
B (acetonitrile with 0.1% formic acid), solvent A (water with 0.1%
formic acid), flow rate of 15.0 mL min−1, and a gradient (start 95% A
for 3.36 min, then linear gradient to 5% A in 30 min, then at 5% A for
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3.36 min, then linear gradient to 95% A in 0.5 min, and then 1.5 min
at 95% A).
The Supporting Information lists 1H NMR and 13C NMR
spectroscopy data as well as high-resolution mass spectroscopy and
LC−MS images (Figures S4−S69).
Synthesis of [3H]Levocetirizine (25−28). Column chromatography
was carried out using prepacked silica gel cartridges (SiliCycle,
Quebec, Canada) on an Isco Companion (Teledyne Isco, NE). 1H
NMR spectra were recorded on a Bruker (600 or 400 MHz) using the
stated solvent. Chemical shifts (δ) in ppm are quoted relative to
CDCl3 (δ 7.26 ppm) and DMSO-d6 (δ 2.50 ppm). Liquid
chromatography−mass spectrometry (LC−MS) data were collected
using a Waters Alliance LC (Waters Corporation, MA) with Waters
ZQ mass detector. Analytical high-performance liquid chromatog-
raphy (HPLC) data were recorded using Agilent 1200 HPLC system
with a β-Ram Flow Scintillation Analyser, using the following
conditions: Waters Sunfire C18, 3.5 μm, 4.6 × 100 mm
2 column at
40 °C, eluting with 5% acetonitrile/water + 0.1% trifluoroacetic acid
(TFA) to 95% acetonitrile/water + 0.1% TFA over a 32 min gradient.
Specific activities were determined gravimetrically with a Packard Tri-
Carb 2100CA Liquid Scintillation Analyser (Packard Instrument
Company Inc., IL) using Ultima Gold cocktail. Reactions with tritium
gas were carried out on a steel manifold obtained from RC Tritec AG
(Teufen, Switzerland). Specific activity was calculated by comparison
of the ratio of tritium/hydrogen or carbon-14/carbon-12 for the
tracer against the unlabeled reference. [3H]Methyl nosylate was
obtained from Quotient Bioresearch as a solution in toluene at 3150
GBq mmol−1. Tritium gas was supplied and absorbed onto a depleted
uranium bed by RC Tritec AG (). All other reagents and solvents
obtained from Sigma-Aldrich and Fisher and were used without
further purification.
Detailed Experimental Procedures. 8-Chloro-11-(1-((4-methyl-
pyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo-
[5,6]cyclohepta[1,2-b]pyridine (3). A mixture of 4-methylnicotinal-
dehyde (93 mg, 0.77 mmol), desloratadine (200 mg, 0.643 mmol),
and NaBH(OAc)3 (218 mg, 1.027 mmol) in DCE (10 mL) was
stirred at room temperature for 12 h. The resulting solution was
diluted with water and extracted with DCM. The organic phase was
washed with satd. aq NaHCO3 solution. The organic layer was dried
over Na2SO4, filtered, and concentrated under vacuum. The crude
mixture was purified by reverse-phase column chromatography
(H2O/MeCN/HCOOH). The product fraction was evaporated,
extracted with DCM/satd. aq Na2CO3 solution, dried (MgSO4),
and concentrated to yield the title compound as a pink foam (170 mg,
64% yield).
1H NMR (500 MHz, CDCl3) δ 8.42−8.22 (m, 3H), 7.39 (dd, J =
7.6, 1.3 Hz, 1H), 7.15−6.97 (m, 5H), 3.48−3.25 (m, 4H), 2.87−2.60
(m, 4H), 2.51−2.20 (m, 7H), 2.19−2.04 (m, 2H). 13C NMR (126
MHz, CDCl3) δ 157.46, 150.18, 148.22, 147.40, 146.49, 139.49,
138.86, 137.76, 137.35, 133.43, 132.62, 132.56, 132.41, 130.79,
128.94, 125.98, 125.43, 122.13, 57.98, 54.80, 54.71, 31.79, 31.40,
30.97, 30.76, 18.81. HRMS: C26H27ClN3 (M + H)
+ calcd: 416.1894,
found: 416.1883. LC−MS: tR = 3.0 min, purity >96% (254 nm), m/z:
416.2 (M + H)+.
8-Chloro-11-(1-((2-methylpyridin-3-yl)methyl)piperidin-4-yli-
dene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (4). A
mixture of desloratadine (155 mg, 0.50 mmol), 3-(chloromethyl)-2-
methylpyridine hydrochloride (116 mg, 0.65 mmol), and K2CO3 (180
mg, 1.30 mmol) in DMF (10 mL) was stirred at room temperature for
18 h. The mixture was diluted with EtOAc, washed with water (2×)
and brine, dried over Na2SO4, filtered, and concentrated under
vacuum. The crude mixture was purified by reverse-phase column
chromatography (H2O/MeCN/HCOOH) to yield the title com-
pound as a pink foam (120 mg, 58% yield).
1H NMR (500 MHz, CDCl3) δ 8.42−8.31 (m, 2H), 7.59 (d, J =
7.0 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.16−7.02 (m, 5H), 3.49−3.29
(m, 4H), 2.88−2.65 (m, 4H), 2.60−2.45 (m, 4H), 2.45−2.26 (m,
3H), 2.23−2.06 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 157.62,
157.44, 147.40, 146.61, 139.50, 138.78, 137.76, 137.32, 137.01,
133.37, 132.69, 132.59, 131.89, 130.78, 128.92, 125.98, 122.11,
121.00, 59.61, 54.92, 54.84, 31.77, 31.41, 30.95, 30.72, 22.26. HRMS:
C26H27ClN3 (M + H)
+ calcd: 416.1888, found: 416.1906. LC−MS: tR
= 2.9 min, purity >98% (254 nm), m/z: 416.2 (M + H)+.
8-Chloro-11-(1-((6-methylpyridin-3-yl)methyl)piperidin-4-yli-
dene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (5). A
mixture of desloratadine (200 mg, 0.643 mmol), 5-(bromomethyl)-2-
methylpyridine hydrobromide (224 mg, 0.836 mmol), and K2CO3
(231 mg, 1.67 mmol) in DMF (10 mL) was stirred at room
temperature for 18 h. The mixture was diluted with EtOAc, washed
with water (2×) and brine, dried over Na2SO4, filtered, and
concentrated under vacuum. The crude mixture was purified by
reverse-phase column chromatography (H2O/MeCN/HCOOH).
The product fraction was evaporated, extracted with DCM/satd. aq
Na2CO3 solution, dried (MgSO4), and concentrated to yield the title
compound as a pink foam (170 mg, 64% yield).
1H NMR (500 MHz, CDCl3) δ 8.41−8.33 (m, 2H), 7.60 (d, J =
7.3 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.16−7.02 (m, 5H), 3.50 (s,
2H), 3.42−3.28 (m, 2H), 2.86−2.68 (m, 4H), 2.57−2.48 (m, 4H),
2.47−2.12 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 157.41, 157.37,
149.71, 146.60, 139.51, 138.20, 137.70, 137.42, 137.32, 133.38,
133.00, 132.69, 130.70, 130.1, 128.95, 126.01, 123.01, 122.14, 59.62,
54.56, 54.45, 31.76, 31.42, 30.64, 30.39, 24.10. HRMS: C26H27ClN3
(M + H)+ calcd: 416.1894, found: 416.1886. LC−MS: tR = 3.0 min,
purity >98% (254 nm), m/z: 416.2 (M + H)+.
8-Chloro-11-(1-(pyridin-3-ylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (6). A mixture of
desloratadine (500 mg, 1.61 mmol), 3-(bromomethyl)-pyridine
hydrobromide (529 mg, 2.09 mmol), and K2CO3 (579 mg, 4.19
mmol) in DMF (10 mL) was stirred at room temperature for 18 h.
The mixture was diluted with EtOAc, washed with water (2×) and
brine, dried over Na2SO4, filtered, and concentrated under vacuum.
The crude mixture was purified by reverse-phase column chromatog-
raphy (H2O/MeCN/HCOOH) to yield the title compound as a pink
foam (430 mg, 66% yield).
1H NMR (500 MHz, CDCl3) δ 8.54−8.43 (m, 2H), 8.37 (d, J =
4.6 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.25−
7.20 (m, 1H), 7.15−7.02 (m, 4H), 3.49 (s, 2H), 3.43−3.27 (m, 2H),
2.88−2.64 (m, 4H), 2.55−2.46 (m, 1H), 2.45−2.25 (m, 3H), 2.21−
2.02 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 157.44, 150.40,
148.60, 146.63, 139.51, 138.60, 137.73, 137.34, 136.81, 133.63,
133.40, 132.79, 132.63, 130.81, 128.96, 126.01, 123.37, 122.15, 60.04,
54.73, 54.66, 31.80, 31.42, 30.89, 30.65. HRMS: C25H25ClN3 (M +
H)+ calcd: 402.1737, found: 402.1733. LC−MS: tR = 3.0 min, purity
>99% (254 nm), m/z: 402.1 (M + H)+.
8-Chloro-11-(1-(pyridin-4-ylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (7). A mixture of
desloratadine (500 mg, 1.61 mmol), 4-(bromomethyl)-pyridine
hydrobromide (529 mg, 2.09 mmol), and K2CO3 (579 mg, 4.19
mmol) in DMF (10 mL) was stirred at room temperature for 18 h.
The mixture was diluted with EtOAc, washed with water (2×) and
brine, dried over Na2SO4, filtered, and concentrated under vacuum.
The crude mixture was purified by reverse-phase column chromatog-
raphy (H2O/MeCN/HCOOH) to yield the title compound as a pink
foam (229 mg, 36% yield).
1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 5.6 Hz, 2H), 8.35 (d, J
= 4.6 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 5.4 Hz, 2H),
7.16−7.00 (m, 4H), 3.46 (s, 2H), 3.42−3.24 (m, 2H), 2.85−2.60 (m,
4H), 2.57−2.23 (m, 4H), 2.20−2.04 (m, 2H). 13C NMR (126 MHz,
CDCl3) δ 157.38, 149.64, 147.76, 146.58, 139.50, 138.46, 137.69,
137.38, 133.41, 132.82, 132.63, 130.78, 128.96, 126.00, 123.89,
122.18, 61.56, 54.85, 54.82, 31.77, 31.40, 30.89, 30.67. HRMS:
C25H25ClN3 (M + H)
+ calcd: 402.1737, found: 402.1741. LC−MS: tR
= 3.0 min, purity >99% (254 nm), m/z: 402.1 (M + H)+.
8-Chloro-11-(1-(pyridin-2-ylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (8). A mixture of
desloratadine (500 mg, 1.61 mmol), 2-(bromomethyl)-pyridine
hydrobromide (529 mg, 2.09 mmol), and K2CO3 (579 mg, 4.19
mmol) in DMF (10 mL) was stirred at room temperature for 18 h.
The mixture was diluted with EtOAc, washed with water (2×) and
brine, dried over Na2SO4, filtered, and concentrated under vacuum.
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The crude mixture was purified by reverse-phase column chromatog-
raphy (H2O/MeCN/HCOOH) to yield the title compound as a pink
foam (399 mg, 62% yield).
1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 4.5 Hz, 1H), 8.36 (d, J
= 4.6 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.2 Hz, 2H),
7.18−6.98 (m, 5H), 3.63 (s, 2H), 3.45−3.27 (m, 2H), 2.87−2.68 (m,
4H), 2.59−2.40 (m, 2H), 2.40−2.27 (m, 2H), 2.26−2.10 (m, 2H).
13C NMR (126 MHz, CDCl3) δ 158.54, 157.56, 149.24, 146.60,
139.52, 138.86, 137.75, 137.28, 136.44, 133.43, 132.62, 132.57,
130.87, 128.96, 125.97, 123.22, 122.11, 122.06, 64.46, 55.07, 55.05,
31.82, 31.40, 30.94, 30.71. HRMS: C25H25ClN3 (M + H)
+ calcd:
402.1737, found: 402.1738. LC−MS: tR = 3.1 min, purity >99% (254
nm), m/z: 402.1 (M + H)+.
8-Chloro-11-(1-(pyrimidin-2-ylmethyl)piperidin-4-ylidene)-6,11-
dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (9). A mixture of
pyrimidine-2-carbaldehyde (91 mg, 0.84 mmol), desloratadine (218
mg, 0.7 mmol), and NaBH(OAc)3 (237 mg, 1.12 mmol) in DCE (10
mL) was stirred at room temperature for 12 h. The resulting solution
was diluted with water and extracted with DCM. The organic phase
was washed with satd. aq NaHCO3. The organic layer was dried over
Na2SO4, filtered, and concentrated under vacuum. The crude mixture
was purified by column chromatography (EtOAc/MeOH/triethyl-
amine (TEA) = 94:4:2, v/v/v) to yield the title compound as a pink
foam (240 mg, 85% yield).
1H NMR (500 MHz, CDCl3) δ 8.71 (d, J = 4.9 Hz, 2H), 8.37 (dd,
J = 4.7, 1.4 Hz, 1H), 7.41 (dd, J = 7.7, 1.4 Hz, 1H), 7.17 (t, J = 4.9 Hz,
1H), 7.14−7.02 (m, 4H), 3.86−3.74 (m, 2H), 3.44−3.30 (m, 2H),
2.89−2.71 (m, 4H), 2.65−2.47 (m, 2H), 2.42−2.25 (m, 4H). 13C
NMR (126 MHz, CDCl3) δ 167.63, 157.64, 157.20, 146.59, 139.48,
138.78, 137.73, 137.20, 133.43, 132.61, 132.59, 130.89, 128.96,
125.97, 122.07, 119.32, 65.09, 55.25, 55.21, 31.85, 31.40, 30.75, 30.50.
HRMS: C24H24ClN4 (M + H)
+ calcd: 403.1684, found: 403.1680.
LC−MS: tR = 2.9 min, purity >99% (254 nm), m/z: 403.2 (M + H)+.
8-Chloro-11-(1-(pyrimidin-4-ylmethyl)piperidin-4-ylidene)-6,11-
dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (10). A mixture of
pyrimidine-4-carbaldehyde (91 mg, 0.84 mmol), desloratadine (218
mg, 0.7 mmol), and NaBH(OAc)3 (237 mg, 1.12 mmol) in DCE (10
mL) was stirred at room temperature for 12 h. The resulting solution
was diluted with water and extracted with DCM. The organic phase
was washed with satd. aq NaHCO3, dried over Na2SO4, filtered, and
concentrated under vacuum. The crude mixture was purified by
column chromatography (EtOAc/MeOH/TEA = 94:4:2, v/v/v) to
yield the title compound as a pink foam (248 mg, 88% yield).
1H NMR (500 MHz, CDCl3) δ 9.11 (s, 1H), 8.67 (d, J = 5.2 Hz,
1H), 8.38 (dd, J = 4.7, 1.2 Hz, 1H), 7.53 (d, J = 5.0 Hz, 1H), 7.42
(dd, J = 8.8, 1.2 Hz, 2H), 7.17−7.02 (m, 4H), 3.62 (s, 2H), 3.44−
3.31 (m, 2H), 2.87−2.71 (m, 4H), 2.61−2.52 (m, 1H), 2.51−2.42
(m, 1H), 2.41−2.31 (m, 2H), 2.30−2.19 (m, 2H). 13C NMR (126
MHz, CDCl3) δ 167.86, 158.57, 157.38, 157.09, 146.59, 139.52,
138.13, 137.71, 137.37, 133.42, 133.05, 132.71, 130.74, 128.96,
126.03, 122.17, 120.13, 63.36, 55.10, 31.79, 31.44, 30.92, 30.70, one
signal overlapping or not visible. HRMS: C24H24ClN4 (M + H)
+
calcd: 403.1684, found: 403.1681. LC−MS: tR = 2.9 min, purity >99%
(254 nm), m/z: 403.2 (M + H)+.
8-Chloro-11-(1-(3-methylbenzyl)piperidin-4-ylidene)-6,11-dihy-
dro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (11). Desloratadine
(500 mg, 1.61 mmol) was added to 3-methylbenzyl bromide (387
mg, 2.09 mmol) and TEA (326 mg, 3.22 mmol) in DCM (10 mL).
The resulting mixture was stirred at room temperature for 18 h. The
solution was then diluted with DCM, washed with a 5% NaHCO3
solution, then with H2O, dried over Na2SO4, filtered, and
concentrated under vacuum. The crude mixture was purified by
reverse-phase column chromatography (H2O/MeCN/HCOOH).
The product fraction was evaporated, extracted with DCM/satd. aq
Na2CO3 solution, dried (MgSO4), and concentrated to yield the title
compound as a pink foam (432 mg, 65% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (dd, J = 4.8, 1.5 Hz, 1H), 7.41
(d, J = 7.7 Hz, 1H), 7.22−6.99 (m, 8H), 3.53−3.28 (m, 4H), 2.90−
2.68 (m, 4H), 2.58−2.25 (m, 7H), 2.21−2.04 (m, 2H). 13C NMR
(126 MHz, CDCl3) δ 157.69, 146.64, 139.52, 139.18, 138.09, 137.84,
137.78, 137.23, 133.42, 132.57, 132.49, 130.92, 129.97, 128.97,
128.06, 127.79, 126.33, 125.99, 122.08, 62.99, 54.89, 54.85, 31.87,
31.44, 30.99, 30.75, 21.46. HRMS: C27H28ClN2 (M + H)
+ calcd:
415.1941, found: 415.1938. LC−MS: tR = 3.6 min, purity >99% (254
nm), m/z: 415.2 (M + H)+.
11-(1-Benzylpiperidin-4-ylidene)-8-chloro-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (12). Desloratadine (500 mg,
1.61 mmol) was added to benzyl bromide (358 mg, 2.09 mmol) and
TEA (326 mg, 3.22 mmol) in DCM (10 mL). The resulting mixture
was stirred at room temperature for 18 h. The solution was then
diluted with DCM and H2O and extraction was performed. The
organic layer was dried over Na2SO4 and filtered. The crude mixture
was purified by reverse-phase column chromatography (H2O/
MeCN/HCOOH). The product fraction was evaporated, extracted
with DCM/satd. aq Na2CO3 solution, dried (MgSO4), and
concentrated to yield the title compound as a pink foam (484 mg,
75% yield).
1H NMR (500 MHz, CDCl3) δ 8.38 (dd, J = 4.8, 1.2 Hz, 1H), 7.42
(dd, J = 7.3, 1.1 Hz, 1H), 7.33−7.20 (m, 5H), 7.17−7.00 (m, 4H),
3.51 (s, 2H), 3.45−3.28 (m, 2H), 2.87−2.69 (m, 4H), 2.58−2.26 (m,
4H), 2.23−2.07 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 157.64,
146.62, 139.51, 139.04, 138.09, 137.81, 137.26, 133.42, 132.58,
132.54, 130.89, 129.23, 128.96, 128.21, 127.06, 125.99, 122.10, 62.91,
54.79, 54.74, 31.85, 31.42, 30.94, 30.71. HRMS: C26H26ClN2 (M +
H)+ calcd: 401.1785, found: 401.1779. LC−MS: tR = 3.4 min, purity
>99% (254 nm), m/z: 401.1 (M + H)+.
8-Chloro-11-(1-(cyclohexylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (13). A mixture of
cyclohexanecarbaldehyde (95 mg, 0.84 mmol), desloratadine (218
mg, 0.70 mmol), and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE
(10 mL) was stirred at room temperature for 12 h. The resulting
solution was diluted with water and extracted with DCM. The organic
phase was washed with satd. aq NaHCO3 solution. The organic layer
was dried over Na2SO4, filtered, and concentrated under vacuum. The
crude mixture was purified by column chromatography (cyclohexane/
EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink
foam (180 mg, 63% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (d, J = 4.6 Hz, 1H), 7.42 (d, J
= 7.6 Hz, 1H), 7.16−7.09 (m, 3H), 7.07 (dd, J = 7.7, 4.8 Hz, 1H),
3.46−3.29 (m, 2H), 2.86−2.74 (m, 2H), 2.74−2.63 (m, 2H), 2.55−
2.46 (m, 1H), 2.44−2.25 (m, 3H), 2.14−1.97 (m, 4H), 1.80−1.60
(m, 5H), 1.50−1.38 (m, 1H), 1.26−1.07 (m, 3H), 0.91−0.78 (m,
2H). 13C NMR (126 MHz, CDCl3) δ 157.77, 146.74, 139.66, 137.96,
137.35, 133.54, 132.70, 132.55, 130.96, 129.07, 126.10, 122.18, 65.45,
55.51, 55.41, 35.32, 32.16, 32.13, 31.94, 31.55, 30.87, 30.62, 26.82,
26.25, one aromatic signal overlapping or not visible. HRMS:
C26H32ClN2 (M + H)
+ calcd: 407.2249, found: 407.2231. LC−MS:
tR = 3.6 min, purity >99% (254 nm), m/z: 407.2 (M + H)
+.
8-Chloro-11-(1-(cyclopentylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (14). A mixture of
cyclopentanecarbaldehyde (83 mg, 0.84 mmol), desloratadine (218
mg, 0.70 mmol), and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE
(10 mL) was stirred at room temperature for 12 h. The resulting
solution was diluted with water and extracted with DCM. The organic
phase was washed with satd. aq NaHCO3 solution. The organic layer
was dried over Na2SO4, filtered, and concentrated under vacuum. The
crude mixture was purified by column chromatography (cyclohexane/
EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink
foam (162 mg, 59% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (d, J = 4.6 Hz, 1H), 7.41 (d, J
= 7.7 Hz, 1H), 7.15−7.08 (m, 3H), 7.06 (dd, J = 7.6, 4.9 Hz, 1H),
3.45−3.29 (m, 2H), 2.86−2.69 (m, 4H), 2.55−2.45 (m, 1H), 2.44−
2.27 (m, 3H), 2.25 (d, J = 7.2 Hz, 2H), 2.16−1.96 (m, 3H), 1.77−
1.67 (m, 2H), 1.61−1.43 (m, 4H), 1.22−1.12 (m, 2H). 13C NMR
(126 MHz, CDCl3) δ 157.87, 146.72, 139.60, 137.98, 137.26, 133.50,
132.63, 132.30, 131.03, 129.03, 126.06, 122.11, 64.50, 55.36, 55.30,
37.60, 31.96, 31.77, 31.52, 31.09, 30.85, 25.30, one aromatic signal
overlapping or not visible. HRMS: C25H30ClN2 (M + H)
+ calcd:
393.2092, found: 393.2091. LC−MS: tR = 3.2 min, purity >98% (254
nm), m/z: 393.2 (M + H)+.
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8-Chloro-11-(1-(2-ethylbutyl)piperidin-4-ylidene)-6,11-dihydro-
5H-benzo[5,6]cyclohepta[1,2-b]pyridine (15). A mixture of 2-
ethylbutanal (85 mg, 0.84 mmol), desloratadine (218 mg, 0.70
mmol), and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE (10 mL)
was stirred at room temperature for 12 h. The resulting solution was
diluted with water and extracted with DCM. The organic phase was
washed with satd. aq NaHCO3 solution. The organic layer was dried
over Na2SO4, filtered, and concentrated under vacuum. The crude
mixture was purified by column chromatography (cyclohexane/
EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink
foam (186 mg, 67% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (dd, J = 4.9, 1.7 Hz, 1H), 7.42
(dd, J = 7.7, 1.6 Hz, 1H), 7.16−7.11 (m, 3H), 7.08 (dd, J = 7.7, 4.8
Hz, 1H), 3.46−3.29 (m, 2H), 2.88−2.69 (m, 4H), 2.61−2.03 (br m,
8H), 1.49−1.24 (m, 5H), 0.84 (t, J = 7.4 Hz, 6H). 13C NMR (126
MHz, CDCl3) δ 157.95, 146.74, 139.83, 139.63, 138.06, 137.25,
133.51, 132.64, 132.27, 131.04, 129.04, 126.06, 122.10, 62.44, 55.60,
55.52, 38.06, 31.99, 31.56, 31.15, 30.92, 24.33, 10.99. HRMS:
C25H32ClN2 (M + H)
+ calcd: 395.2249, found: 395.2244. LC−MS: tR
= 3.3 min, purity >98% (254 nm), m/z: 395.2 (M + H)+.
8-Chloro-11-(1-(cyclobutylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (16). A mixture of
(bromomethyl)cyclobutane (208 mg, 1.40 mmol), desloratadine (218
mg, 0.70 mmol), and 60% NaH dispersion (41.6 mg, 1.05 mmol) in
DMF (10 mL) was stirred at room temperature for 10 h. The
resulting solution was diluted with water and extracted with DCM.
The organic phase was washed with satd. aq NaHCO3 solution. The
organic layer was dried over Na2SO4, filtered, and concentrated under
vacuum. The crude mixture was purified by column chromatography
(cyclohexane/EtOAc/TEA = 40/58/2, v/v/v) to yield the title
compound as a pink foam (150 mg, 56% yield).
1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 4.9, 1.4 Hz, 1H), 7.41
(d, J = 7.6 Hz, 1H), 7.15−7.08 (m, 3H), 7.06 (dd, J = 7.7, 4.8 Hz,
1H), 3.44−3.30 (m, 2H), 2.85−2.73 (m, 2H), 2.74−2.66 (m, 2H),
2.56−2.44 (m, 2H), 2.43−2.25 (m, 5H), 2.12−1.96 (m, 4H), 1.92−
1.80 (m, 1H), 1.79−1.70 (m, 1H), 1.69−1.58 (m, 2H). 13C NMR
(126 MHz, CDCl3) δ 157.78, 146.73, 139.60, 139.24, 137.93, 137.29,
133.49, 132.66, 132.46, 130.99, 129.03, 126.07, 122.13, 65.28, 55.13,
55.07, 34.36, 31.94, 31.53, 31.05, 30.80, 28.32, 18.93. HRMS:
C24H28ClN2 (M + H)
+ calcd: 379.1936, found: 379.1923. LC−MS: tR
= 3.1 min, purity >96% (254 nm), m/z: 379.2 (M + H)+.
8-Chloro-11-(1-(cyclopropylmethyl)piperidin-4-ylidene)-6,11-di-
hydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (17). A mixture of
cyclopropanecarboxaldehyde (59 mg, 0.84 mmol), desloratadine (218
mg, 0.70 mmol), and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE
(10 mL) was stirred at room temperature for 12 h. The resulting
solution was diluted with water and extracted with DCM. The organic
phase was washed with satd. aq NaHCO3 solution. The organic layer
was dried over Na2SO4, filtered, and concentrated under vacuum. The
crude mixture was purified by column chromatography (cyclohexane/
EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink
foam (132 mg, 52% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (dd, J = 4.8, 1.6 Hz, 1H), 7.42
(dd, J = 7.7, 1.6 Hz, 1H), 7.16−7.09 (m, 3H), 7.07 (dd, J = 7.6, 4.7
Hz, 1H), 3.44−3.30 (m, 2H), 2.93−2.73 (m, 4H), 2.59−2.50 (m,
1H), 2.48−2.31 (m, 3H), 2.24 (d, J = 6.5 Hz, 2H), 2.21−2.12 (m,
2H), 0.92−0.79 (m, 1H), 0.53−0.43 (m, 2H), 0.06 (app q, 2H). 13C
NMR (126 MHz, CDCl3) δ 157.78, 146.76, 139.61, 139.24, 137.94,
137.32, 133.51, 132.70, 132.58, 131.01, 129.05, 126.10, 122.17, 63.74,
55.10, 55.05, 31.96, 31.55, 31.05, 30.80, 8.52, 4.11, 4.09. HRMS:
C23H26ClN2 (M + H)
+ calcd: 365.1779, found: 365.1773. LC−MS: tR
= 2.9 min, purity >99% (254 nm), m/z: 365.1 (M + H)+.
8-Chloro-11-(1-cyclohexylpiperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (18). A mixture of cyclo-
hexanone (82 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol),
and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE (10 mL) was stirred
at room temperature for 12 h. The resulting solution was diluted with
water and extracted with DCM. The organic phase was washed with
satd. aq NaHCO3 solution. The organic layer was dried over Na2SO4,
filtered, and concentrated under vacuum. The crude mixture was
purified by column chromatography (cyclohexane/EtOAc/TEA =
40/58/2, v/v/v) to yield the title compound as a pink foam (192 mg,
70% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (dd, J = 4.8, 1.5 Hz, 1H), 7.42
(d, J = 7.6, 1H), 7.16−7.09 (m, 3H), 7.06 (dd, J = 7.7, 4.8 Hz, 1H),
3.44−3.30 (m, 2H), 2.86−2.71 (m, 4H), 2.53−2.44 (m, 1H), 2.44−
2.23 (m, 6H), 1.88−1.69 (m, 4H), 1.60 (app d, J = 13.6 Hz, 1H),
1.27−1.12 (m, 4H), 1.12−1.00 (m, 1H). 13C NMR (126 MHz,
CDCl3) δ 157.92, 146.74, 139.86, 139.60, 137.96, 137.25, 133.52,
132.64, 132.24, 131.10, 129.05, 126.06, 122.12, 63.76, 50.71, 50.59,
32.00, 31.64, 31.54, 31.38, 29.05, 28.91, 26.47, 26.17. HRMS:
C25H30ClN2 (M + H)
+ calcd: 393.2092, found: 393.2083. LC−MS: tR
= 3.1 min, purity >99% (254 nm), m/z: 393.2 (M + H)+.
8-Chloro-11-(1-cyclopentylpiperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (19). A mixture of cyclo-
pentanone (70 mg, 0.84 mmol), desloratadine (218 mg, 0.70
mmol), and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE (10 mL)
was stirred at room temperature for 12 h. The resulting solution was
diluted with water and extracted with DCM. The organic phase was
washed with satd. aq NaHCO3 solution. The organic layer was dried
over Na2SO4, filtered, and concentrated under vacuum. The crude
mixture was purified by column chromatography (cyclohexane/
EtOAc/TEA = 40/58/2, v/v/v) to yield the title compound as a pink
foam (189 mg, 71% yield).
1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 4.8, 1H), 7.41 (d, J =
7.6 Hz, 1H), 7.15−7.08 (m, 3H), 7.06 (dd, J = 7.7, 4.8 Hz, 1H),
3.44−3.29 (m, 2H), 2.87−2.72 (m, 4H), 2.57−2.39 (m, 3H), 2.38−
2.29 (m, 2H), 2.19−2.07 (m, 2H), 1.87−1.74 (m, 2H), 1.70−1.59
(m, 2H), 1.55−1.45 (m, 2H), 1.45−1.33 (m, 2H). 13C NMR (126
MHz, CDCl3) δ 157.81, 146.73, 139.59, 139.45, 137.87, 137.26,
133.52, 132.66, 132.27, 131.05, 129.04, 126.07, 122.13, 67.41, 54.13,
54.10, 31.98, 31.53, 31.13, 30.85, 30.70, 24.34. HRMS: C24H28ClN2
(M + H)+ calcd: 379.1936, found: 379.1921. LC−MS: tR = 3.0 min,
purity >99% (254 nm), m/z: 379.1 (M + H)+.
8-Chloro-11-(1-cyclobutylpiperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (20). A mixture of cyclo-
butanone (59 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol),
and NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE (10 mL) was stirred
at room temperature for 12 h. The resulting solution was diluted with
water and extracted with DCM. The organic phase was washed with
satd. aq NaHCO3 solution. The organic layer was dried over Na2SO4,
filtered, and concentrated under vacuum. The crude mixture was
purified by column chromatography (cyclohexane/EtOAc/TEA =
40/58/2, v/v/v) to yield the title compound as a pink foam (145 mg,
57% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (d, J = 4.6 Hz, 1H), 7.42 (d, J
= 7.6 Hz, 1H), 7.15−7.09 (m, 3H), 7.09−7.05 (m, 1H), 3.45−3.30
(m, 2H), 2.87−2.74 (m, 2H), 2.74−2.60 (m, 3H), 2.55−2.46 (m,
1H), 2.46−2.28 (m, 3H), 2.05−1.86 (m, 6H), 1.74−1.57 (m, 2H).
13C NMR (126 MHz, CDCl3) δ 157.78, 146.77, 139.60, 139.01,
137.89, 137.33, 133.53, 132.78, 132.74, 130.99, 129.09, 126.12,
122.21, 60.32, 51.24, 51.23, 31.97, 31.53, 30.65, 30.38, 27.42, 14.35.
HRMS: C23H26ClN2 (M + H)
+ calcd: 365.1779, found: 365.1772.
LC−MS: tR = 2.9 min, purity >99% (254 nm), m/z: 365.2 (M + H)+.
8-Chloro-11-(1-cyclopropylpiperidin-4-ylidene)-6,11-dihydro-
5H-benzo[5,6]cyclohepta[1,2-b]pyridine (21). A mixture of (1-
ethoxycyclopropoxy)trimethylsilane (347 mg, 2.00 mmol), deslor-
atadine (622 mg, 2.00 mmol), AcOH (111 mg, 2.00 mmol), and
sodium triacetoxyborohydride (604 mg, 3.20 mmol) in DCM (10
mL) was stirred at room temperature for 48 h. The resulting solution
was diluted with water and extracted with DCM. The organic phase
was washed with satd. aq NaHCO3 solution. The organic layer was
dried over Na2SO4, filtered, and concentrated under vacuum. The
crude mixture was purified by reverse-phase column chromatography
(H2O/MeCN/HCOOH). The product fraction was evaporated,
extracted with DCM/satd. aq Na2CO3 solution, dried (MgSO4),
and concentrated to yield the title compound as a pink foam (124 mg,
17% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (dd, J = 4.9, 1.5 Hz, 1H), 7.43
(dd, J = 7.8, 1.6 Hz, 1H), 7.16−7.10 (m, 3H), 7.08 (dd, J = 7.7, 4.7
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Hz, 1H), 3.45−3.32 (m, 2H), 2.92−2.74 (m, 4H), 2.50−2.42 (m,
1H), 2.40−2.26 (m, 5H), 1.60−1.50 (m, 1H), 0.47−0.35 (m, 4H).
13C NMR (126 MHz, CDCl3) δ 157.85, 146.75, 139.58, 139.35,
137.95, 137.30, 133.51, 132.69, 132.66, 131.01, 129.08, 126.10,
122.17, 55.16, 38.39, 31.97, 31.52, 31.00, 30.74, 6.09, one aliphatic
signal overlapping or not visible. HRMS: C22H24ClN2 (M + H)
+
calcd: 351.1623, found: 351.1610. LC−MS: tR = 2.9 min, purity >98%
(254 nm), m/z: 351.2 (M + H)+.
8-Chloro-11-(1-isopropylpiperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (22). A mixture of propan-2-
one (49 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and
NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at
room temperature for 12 h. The resulting solution was diluted with
water and extracted with DCM. The organic phase was washed with
satd. aq NaHCO3 solution. The organic layer was dried over Na2SO4,
filtered, and concentrated under vacuum. The crude mixture was
purified by column chromatography (cyclohexane/EtOAc/TEA =
40/58/2, v/v/v) to yield the title compound as a pink foam (101 mg,
41% yield).
1H NMR (500 MHz, CDCl3) δ 8.39 (dd, J = 4.8, 1.7 Hz, 1H), 7.43
(dd, J = 7.7, 1.7 Hz, 1H), 7.16−7.10 (m, 3H), 7.08 (dd, J = 7.6, 4.8
Hz, 1H), 3.45−3.32 (m, 2H), 2.87−2.69 (m, 5H), 2.55−2.47 (m,
1H), 2.46−2.22 (m, 5H), 1.04 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 157.87, 146.76, 139.62,
137.93, 137.30, 133.55, 132.70, 132.43, 131.08, 129.08, 126.10,
122.17, 54.57, 50.34, 50.19, 32.01, 31.56, 31.40, 31.13, 18.60, 18.45,
one aromatic signal overlapping or not visible. HRMS: C22H26ClN2
(M + H)+ calcd: 353.1779, found: 353.1770. LC−MS: tR = 2.9 min,
purity >95% (254 nm), m/z: 353.2 (M + H)+.
8-Chloro-11-(1-ethylpiperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine (23). A mixture of acetaldehyde
(37 mg, 0.84 mmol), desloratadine (218 mg, 0.70 mmol), and
NaBH(OAc)3 (238 mg, 1.12 mmol) in DCE (10 mL) was stirred at
room temperature for 12 h. The resulting solution was diluted with
water and extracted with DCM. The organic phase was washed with
satd. aq NaHCO3 solution. The organic layer was dried over Na2SO4,
filtered, and concentrated under vacuum. The crude mixture was
purified by column chromatography (cyclohexane/EtOAc/TEA =
40/58/2, v/v/v) to yield the title compound as a pink foam (65 mg,
27% yield).
1H NMR (300 MHz, CDCl3) δ 8.40 (dd, J = 4.8, 1.6 Hz, 1H), 7.43
(dd, J = 7.7, 1.7 Hz, 1H), 7.19−7.11 (m, 3H), 7.08 (dd, J = 7.7, 4.8
Hz, 1H), 3.48−3.29 (m, 2H), 2.91−2.70 (m, 4H), 2.62−2.50 (m,
1H), 2.50−2.29 (m, 5H), 2.24−2.05 (m, 2H), 1.09 (t, J = 7.2 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 157.76, 146.78, 139.64, 139.14,
137.93, 137.36, 133.54, 132.75, 132.66, 131.01, 129.08, 126.13,
122.21, 54.65, 54.59, 52.31, 31.97, 31.57, 31.05, 30.79, 12.23. HRMS:
C21H24ClN2 (M + H)
+ calcd: 339.1623, found: 339.1608. LC−MS: tR
= 2.7 min, purity >97% (254 nm), m/z: 339.1 (M + H)+.
8-Chloro-11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine fumarate (24). To a solution
of desloratadine (5.00 g, 16.1 mmol) in DCM (150 mL) were added
MeOH (75 mL), aq formaldehyde solution (ca. 13.4 M, 2.40 mL,
32.2 mmol) and AcOH (1.29 mL, 22.5 mmol), and the resulting
mixture was stirred at room temperature for 15 min. Subsequently,
NaBH(OAc)3 (5.11 g, 24.1 mmol) was added and the resulting
mixture was stirred for 1.5 h at room temperature. The reaction
mixture was diluted with 1 M aqueous NaOH (600 mL) and
extracted with DCM (2 × 200 mL). The combined organic phases
were washed with brine (200 mL), dried over Na2SO4, filtered, and
concentrated in vacuo. Purification by flash column chromatography
(DCM/MeOH/TEA 190:5:5) gave the free base (3.96 g), which was
subsequently converted to the fumaric acid salt to obtain the title
compound as a white solid (4.27 g, 60%).
1H NMR (500 MHz, DMSO-d6) δ 8.36−8.32 (m, 1H), 7.57 (d, J =
7.6 Hz, 1H), 7.31 (d, J = 2.0 Hz, 1H), 7.24−7.17 (m, 2H), 7.09 (d, J
= 8.2 Hz, 1H), 6.55 (s, 2H), 3.37−3.24 (m, 2H), 2.89−2.77 (m, 4H),
2.48−2.38 (m, 4H), 2.36 (s, 3H), 2.31−2.22 (m, 2H). 13C NMR (126
MHz, DMSO-d6) δ 167.0, 156.7, 146.4, 140.2, 137.8, 137.5, 135.3,
134.6, 133.3, 133.2, 131.6, 130.7, 129.0, 125.7, 122.4, 55.1, 44.2, 30.9,
30.6, 29.2, 29.1. HRMS: C20H22ClN2 (M + H)
+ calcd: 325.1466,
found 325.1452. LC−MS: tR = 2.9 min, purity >99% (254 nm), m/z:
324.9 (M + H)+.
(4-Chlorophenyl)(4-iodophenyl)methanol (25). (4-Chlorophen-
yl)magnesium bromide (1.0 M in Et2O) (3.23 mL, 3.23 mmol) was
added dropwise over 15 min to a stirred solution of 4-
iodobenzaldehyde (500 mg, 2.16 mmol) in Et2O (4 mL) at 0 °C
under nitrogen. The mixture was allowed to warm to room
temperature and stirred for a further 16 h. Satd. aq NH4Cl (1 mL)
was added carefully (CAUTION! Exotherm and vigorous bubbling).
After bubbling had ceased, the mixture was partitioned between Et2O
(10 mL) and satd. aq NH4Cl (5 mL). The organic phase was washed
with brine (5 mL), dried (MgSO4), filtered, and evaporated to give
the title compound (655 mg, 88%) as a cream solid.
1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.62 Hz, 2H), 7.27−
7.13 (m, 4H), 7.02 (d, J = 8.36 Hz, 2H), 5.68 (s, 1H).
1-Chloro-4-(chloro(4-iodophenyl)methyl)benzene (26). SOCl2
(0.138 mL, 1.89 mmol) was added dropwise to a stirred solution of
25 (0.65 g, 1.89 mmol) in DCM (9.29 mL) at room temperature.
After 20 h, the solvent was evaporated under vacuum to give the
product (0.653 g, 1.799 mmol, 95%) as a purple solid.
1H NMR (400 MHz, CDCl3) δ 7.63−7.58 (m, 2H), 7.27−7.16 (m,
4H), 7.07−7.02 (m, 2H), 5.94 (s, 1H).
2-(4-((4-Chlorophenyl)(4-iodophenyl)methyl)piperazin-1-yl)-
ethanol (27). A solution of 2-(piperazin-1-yl)ethanol (0.206 g, 1.58
mmol) in toluene (1 mL) was added to 26 (0.637 g, 1.75 mmol) and
the mixture was stirred at 80 °C under nitrogen for 20 h. The mixture
was diluted with DCM and purified by ion-exchange chromatography
(strong cation exchange) eluting with 1 M NH3/MeOH. Fractions
containing product were purified by flash silica chromatography
(elution gradient 0−5% MeOH−NH3 (3.5 M) in DCM) to afford the
product (165 mg, 0.361 mmol, 21%) as a white solid.
1H NMR (600 MHz, DMSO-d6) 7.65 (d, J = 8.1 Hz, 2H), 7.39 (d,
J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H),
4.15 (s, 1H), 4.32 (s, 1H), 3.5−3.42 (m, 2H), 2.48−2.41 (m, 4H),
2.38 (t, J = 6.0 Hz, 2H), 2.33−2.24 (m, 4H). LC−MS (ESI) m/z 457.
(S)-2-(2-(4-((4-Chlorophenyl)(4-iodophenyl)methyl)piperazin-1-
yl)ethoxy)acetic Acid (28). KOH (79 mg, 1.41 mmol) was added to a
stirred solution of 27 (161 mg, 0.35 mmol) in DMF (641 μL) at 0 °C
and the mixture was stirred for 90 min. Sodium 2-chloroacetate (82
mg, 0.70 mmol) was added and the mixture was stirred for 3 h. Water
(3 mL) was added and the pH was adjusted to 9−10 with aq HCl (1
M). The mixture was washed with EtOAc (2 × 1 mL) and the pH was
adjusted to 4−5 with aq HCl (1 M). The mixture was extracted with
DCM (3 × 2 mL). The combined DCM phases were washed with
brine (2 mL), dried (MgSO4), filtered, and evaporated to give, after
trituration with Et2O, racemic product (103 mg, 0.200 mmol, 57%) as
an off-white solid.
1H NMR (600 MHz, DMSO-d6) 7.69−7.65 (m, 2H), 7.44−7.4 (m,
2H), 7.38−7.34 (m, 2H), 7.22 (d, J = 8.4 Hz, 2H), 3.87 (s, 2H), 4.39
(s, 1H), 3.62 (t, J = 5.5 Hz, 2H), 2.85−2.63 (m, 6H), 2.46−2.27 (m,
4H). LC−MS (ESI) m/z 515.
The stereoisomers were separated by chromatography using a
Chiralpak OD column, 5 μm silica, 20 mm diameter, 250 mm length,
eluting with 95/05/0.2/0.1 mixture of MeCN/MeOH/AcOH/TEA
to give the desired isomer (first eluted) (S)-2-(2-(4-((4-
chlorophenyl)(4-iodophenyl)methyl)piperazin-1-yl)ethoxy)acetic
acid (S)-28 (7.8 mg)
(R)-5-(4-((4-Chlorophenyl)([4-3H]phenyl)methyl)piperazin-1-yl)-
pentanoic Acid ([3H]Levocetirizine). Precursor (S)-28 (0.8 mg, 1.55
μmol), Pd (10% on carbon, 0.5 mg, 0.47 μmol), and Et3N (5 μL, 0.04
mmol) were mixed in EtOH (200 μL). The flask was fitted to the
tritium manifold. The mixture was freeze−pump−thaw degassed and
was then stirred under tritium gas (63.5 GBq) at 162 mbar for 2.5 h.
The reaction mixture was filtered through a poly(tetrafluoroethylene)
filter (Whatman 0.45 μm) and washed thoroughly with more EtOH
(5 mL). The solution was lyophilized to remove labile tritium, more
EtOH (5 mL) was addeAmyloid Inhbitorsd, and the mixture was
again lyophilized. Purification by preparative HPLC (Waters XBridge
C18 column, 5 μm, 4.6 × 150 mm2) using decreasingly polar mixtures
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of water (containing 0.1% TFA) and MeCN as eluents followed by
further preparative HPLC (Waters XBridge C18 column, 5 μm, 4.6 ×
150 mm2), using decreasingly polar mixtures of water (containing
0.1% ammonia) and MeCN as eluents, afforded [3H]levocetirizine
(728 MBq), which was dissolved in EtOH (10 mL) for storage as a
colorless solution.
Radiochemical purity >98% by HPLC. Chiral purity 93%
enantiomeric excess by HPLC (obtained on ethyl ester derivative
by standing in ethanol with TFA for 3 days). LC−MS (ESI) m/z 391
[M + H]+. 1H NMR (640 MHz, DMSO-d6) 7.20 (t, J = 7.8). Specific
activity by mass spectrometry: 956 GBq mmol−1.
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